Physician profile
Keely Hoban
NPI 1952630501
$2,556.48
in general payments reported to CMS, 2019-2025
9 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.19 · 2020: $143 · 2021: $52.01 · 2022: $1,537 · 2023: $217 · 2024: $190 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,946.62 | 2020-2025 | Myday Contact Lens, Misight Contact Lens, Ortho-K Contact Lens |
| Johnson & Johnson Vision Care, INC. | $297.15 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $61.86 | 2019-2025 | Precision7 |
| Carl Zeiss Meditec USA, INC. | $52.87 | 2025 | Cirrus Hd-Oct |
| Amgen INC. | $47.33 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $43.86 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $42.99 | 2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $32.22 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $31.58 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keely Hoban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.